Summary of CG Oncology FY Conference Call Company Overview - **Company**: CG Oncology (NasdaqGS:CGON) - **Focus**: Development of Credo, a treatment for bladder cancer, particularly targeting BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC) Key Points and Arguments Clinical Trials and Efficacy - **Credo Administration**: Administered via catheter, similar to BCG, requiring no retraining for urologists [1] - **BOND-003 Trial**: - Cohort C shows a complete response (CR) rate of 75.5% in over 110 patients, with a 12-month CR rate of 46.4% [1] - 90% of patients with CR at 12 months remain in CR at 24 months, outperforming competitors like Keytruda, which has a 9% CR rate at 2 years [2] - **Adjuvant Therapy**: Credo is trending positively as an adjuvant therapy in patients with resected tumors [3] - **PIVOT-006 Trial**: - Unique inclusion of high-grade Ta lesions under 3 cm, focusing on recurrence-free survival [4] - No restrictions on FGFR wild type or mutants [5] - **CORE-008 Trial**: - Tested Credo in a BCG-naive population, achieving an 88% complete response rate in optimized installation cohort [6] Market Opportunity - **Pricing and Market Size**: - Pricing for BCG-unresponsive market ranges from $200,000 to $700,000 annually [11] - Treatment duration: up to 30 doses over three years for BCG-unresponsive patients, and 14 doses over one year for intermediate-risk patients [11] - **Commercial Strategy**: - Focus on a concentrated market with 300 accounts representing over 70% of business [8] - Building a sales team of 75-80 individuals with experience in bladder cancer [39] Regulatory and Submission Updates - **BLA Submission**: - Expected completion in 2026, with ongoing dialogue with the FDA regarding submission requirements [18][19] - Focus on CMC (Chemistry, Manufacturing, and Controls) processes for submission [20] - **Data Readouts**: Upcoming data from PIVOT-006 and cohort CX, which includes Credo plus gemcitabine [8] Competitive Landscape - **Differentiation**: Credo's unique profile and data position it as a first-choice therapy for patients with BCG-unresponsive disease [45] - **Market Dynamics**: - High-risk market expected to be larger than intermediate-risk, but penetration rates will determine actual market size [70] - Learning from previous product launches to refine commercial strategy [41] Additional Insights - **Retreatment Potential**: Credo shows a 50% conversion rate to CR upon reinduction in BCG-unresponsive patients [15] - **Patient-Centric Approach**: Emphasis on preserving bladder function is critical for patient acceptance and treatment adherence [42] Important but Overlooked Aspects - **Learning from Competitors**: CG Oncology aims to leverage insights from other companies' challenges to enhance its market entry strategy [79] - **Long-term Durability**: The focus on long-term CR rates and patient outcomes is a significant aspect of Credo's value proposition [42] This summary encapsulates the critical insights from CG Oncology's FY conference call, highlighting the company's strategic direction, clinical data, market potential, and regulatory considerations.

Summary of CG Oncology Conference Call Company Overview - **Company**: CG Oncology - **Product**: Credostimogene (Credo) - **Indication**: Non-muscle invasive bladder cancer (NMIBC), specifically targeting BCG unresponsive patients Key Points Current Status and Development - CG Oncology is preparing to file its first Biologics License Application (BLA) for Credo targeting BCG unresponsive, high-risk NMIBC, addressing approximately 25,000 patients in the U.S. [3][48] - The company reported a 24-month complete response (CR) rate of 41.8%, with 46 out of 110 patients achieving CR, indicating that up to 42% of patients can preserve their bladders for two years post-treatment [4][49] - In comparison, Keytruda has a 40% CR rate at three months, highlighting the significance of Credo's long-term efficacy [5] Clinical Trials - Enrollment for a second Phase 3 trial targeting intermediate-risk NMIBC patients has been completed, ahead of internal projections by ten months [6] - The trial aims to prevent recurrence in BCG naive patients and will not require genetic testing, potentially leading to a broader label [7] - The company is also working on optimizing the administration process, reducing it from a five-step to a two-step process, which will save 15-20 minutes in administration time [10] Regulatory Considerations - The FDA has specific guidance for single-arm trials for BCG unresponsive indications, which has been successfully navigated by other agents [14][15] - CG Oncology is focused on ensuring that the Chemistry, Manufacturing, and Controls (CMC) aspects are robust to avoid issues during the BLA submission [19][39] - The company has engaged experienced personnel to oversee the CMC process and has conducted mock inspections to prepare for FDA evaluations [26][21] Market Dynamics - There is a significant unmet need in the NMIBC market, particularly due to ongoing BCG shortages and the demand for durable therapies [48] - The conversation between physicians and patients often revolves around the duration of response and safety of new treatments post-BCG failure [49] - CG Oncology aims to position Credo as a backbone therapy in the NMIBC treatment landscape, with ongoing trials exploring its use in combination with other therapies [64] Competitive Landscape - The company is aware of other agents in the market and is focused on differentiating Credo through its efficacy and safety profile [62][65] - CG Oncology plans to learn from the market entry of competitors to refine its pricing strategy, which could range from $200,000 to $600,000 per year [67] Future Outlook - The company anticipates filing the BLA in the fourth quarter of 2025, with a rolling submission strategy [38] - CG Oncology is also exploring the treatment-naive setting and aims to establish Credo's efficacy as a monotherapy before considering combination therapies [55][56] Additional Insights - The concentration of NMIBC patients is primarily in high-volume centers, with a small number of urologists managing the majority of cases [53][54] - The company is committed to addressing the logistical aspects of product handling and administration to ensure ease of use in clinical settings [27][28] This summary encapsulates the critical insights from the CG Oncology conference call, highlighting the company's strategic direction, clinical advancements, and market positioning.